DFS and OS rates for patients who underwent BMT
| Type of BMT . | Group 1, daunorubicin (n = 78) . | Group 2, idarubicin (n = 113) . | Groups 1 and 2 combined (n = 191) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n . | DFS, %(P) . | OS, % (P) . | n . | DFS, %(P) . | OS, % (P) . | n . | DFS, %(P) . | OS, % (P) . | |
| Autologous | 62 | 57 | 62 | 94 | 47 | 64 | 156 | 52 | 63 |
| Allogeneic | 16 | 75 (.22) | 63 (.99) | 19 | 63 (.63) | 72 (.93) | 35 | 69 (.12) | 79 (.23) |
| Type of BMT . | Group 1, daunorubicin (n = 78) . | Group 2, idarubicin (n = 113) . | Groups 1 and 2 combined (n = 191) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n . | DFS, %(P) . | OS, % (P) . | n . | DFS, %(P) . | OS, % (P) . | n . | DFS, %(P) . | OS, % (P) . | |
| Autologous | 62 | 57 | 62 | 94 | 47 | 64 | 156 | 52 | 63 |
| Allogeneic | 16 | 75 (.22) | 63 (.99) | 19 | 63 (.63) | 72 (.93) | 35 | 69 (.12) | 79 (.23) |
Results for autologous BMT vs allogeneic BMT were determined using χ2 analysis.